In this context, the present study demonstrates a previously unknown dual IL-1β-triggered mechanism of TF expression in lung cancer cells and thus defines upstream targets for pharmacotherapeutic intervention to block the formation of protumorigenic TF. Here, IL1B is linked to lung carcinoma.